Compounds > ly 295337
Page last updated: 2024-11-12

ly 295337

Description

LY 295337: a cyclic depsipeptide antifungal antibiotic produced by Aureobasidium pullulans [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9919816
CHEMBL ID1793802
SCHEMBL ID301215
MeSH IDM0252747

Synonyms (25)

Synonym
D03057
basifungin (usan/inn)
ly295337
valine, 3-hydroxy-n-(n-(n-(n-(1-(n-(n-(n-(2-hydroxy-3-methyl-1-oxopentyl)-n-methylvalyl)phenylalanyl)-n-methylphenylalanyl)prolyl)alloisoleucyl)-n-methylvalyl)leucyl)-n-methyl-, alpha-1-lactone
basifungin [usan:inn]
ly 295337
n-((2r,3r)-2-hydroxy-3-methylvaleryl)-n-methyl-l-valyl-l-phenylalanyl-n-methyl-l-phenylalanyl-l-prolyl-l-alloisoleucyl-n-methyl-l-valyl-l-leucyl-3-hydroxy-n-methyl-l-valine alpha1-lactone
CHEMBL1793802 ,
vv0uso6i6u ,
r106-1
nk 204
unii-vv0uso6i6u
ly-295337
bdbm50408926
SCHEMBL301215
n-((2r,3r)-2-hydroxy-3-methylvaleryl)-n-methyl-l-valyl-l-phenylalanyl-n-methyl-l-phenylalanyl-l-prolyl-l-alloisoleucyl-n-methyl-l-valyl-l-leucyl-3-hydroxy-n-methyl-l-valine .alpha.(sub 1)-lactone
basifungin [inn]
basifungin [usan]
DTXSID201017531
basifungin; aba
Q27292033
MS-31962
(3s,6s,9s,12r,15s,18s,21s,24s,27s)-3,6-dibenzyl-12,24-bis[(2r)-butan-2-yl]-15-(2-hydroxypropan-2-yl)-4,10,16,22-tetramethyl-18-(2-methylpropyl)-9,21-di(propan-2-yl)-13-oxa-1,4,7,10,16,19,22,25-octazabicyclo[25.3.0]triacontane-2,5,8,11,14,17,20,23,26-nonon
HY-P1975
CS-0104069
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Pathways (1)

PathwayProteinsCompounds
sphingolipid biosynthesis (plants)1223

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Inositol phosphorylceramide synthaseCandida albicans SC5314IC50 (µMol)0.00020.00020.00040.0006AID542410
Inositol phosphorylceramide synthaseCandida albicans SC5314Ki0.00040.00020.00040.0005AID542405; AID542410
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)2.27000.00022.318510.0000AID680138
Inositol phosphorylceramide synthase catalytic subunit AUR1Saccharomyces cerevisiae S288CIC50 (µMol)0.00020.00020.02160.0430AID542411
Inositol phosphorylceramide synthase catalytic subunit AUR1Saccharomyces cerevisiae S288CKi0.70010.00020.70011.4000AID542406; AID542407
Aureobasidin-resistance proteinAspergillus fumigatusIC50 (µMol)0.00020.00020.00020.0002AID542412
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID1759442Hemolytic activity in human RBC at 8 ug/ml incubated for 30 mins2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759460Antifungal activity against Aspergillus niger incubated for 48 hrs by broth microdilution method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID680138TP_TRANSPORTER: inhibition of Calcein-AM efflux (Calcein-AM: 0.25 uM) in CEM/VLB100 cells2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
Aureobasidins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC-transporter.
AID1759436Antifungal activity against Cryptococcus neoformans PFCC 93-589 after 7 days in presence of sorbitol by microdilution assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759426Synergistic antifungal activity against Cryptococcus neoformans PFCC 93-589 assessed as fractional inhibitory concentration index in presence of fluconazole by checkerboard microtiter assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759431Inhibition of ergosterol biosynthesis in Cryptococcus neoformans PFCC 93-589 cell membrane assessed as ergosterol content at 1 times MIC incubated for 48 hrs by UV-visible spectrophotometric analysis (Rvb = 0.134 No_unit)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1233883Antifungal activity against Aspergillus fumigatus by broth dilution method2015ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6
Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A.
AID1759466Antifungal activity against Candida parapsilosis incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759433Antifungal activity against Cryptococcus neoformans PFCC 93-589 after 2 days in absence of sorbitol by microdilution assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID542406Inhibition of Saccharomyces cerevisiae SJ21R inositol phosphorylceramide synthase preincubated for 30 mins2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID542412Inhibition of Aspergillus fumigatus inositol phosphorylceramide synthase2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID1759467Antifungal activity against Candida krusei incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID542416Irreversible inhibition of Saccharomyces cerevisiae SJ21R inositol phosphorylceramide synthase preincubated for 30 mins2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID1759451Cytotoxicity against human HEK293 cells assessed as inhibition of cell viability at 2 times MIC incubated for 24 hrs by MTT assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759468Antifungal activity against Cryptococcus neoformans PFCC 93-589 assessed as half minimum inhibitory concentration by broth microdilution assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759461Antifungal activity against Aspergillus fumigatus incubated for 48 hrs by broth microdilution method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID542408Noncompetitive inhibition of aureobasidin A-resistant Saccharomyces cerevisiae inositol phosphorylceramide synthase preincubated for 30 mins by Michaelis-Menten plot2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID1759453Induction of morphological changes in Cryptococcus neoformans PFCC 93-589 assessed as deposition of lipid globules at 2 ug/ml after 48 hrs by TEM analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759450Cytotoxicity against human HEK293 cells assessed as cell survival at 1 times MIC incubated for 24 hrs by MTT assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759428Induction of morphological changes in Cryptococcus neoformans PFCC 93-589 assessed as disorganization of cytoplasmic content at 2 ug/ml after 48 hrs by TEM analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID542409Inhibition of Saccharomyces cerevisiae SJ21R inositol phosphorylceramide synthase2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID1759437Antifungal activity against Cryptococcus neoformans PFCC 93-589 assessed as increase in extracellular potassium leakage at 2 times MIC incubated up to 12 hrs measured per mg dry weight of cell by spectrophotometric method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID554742Inhibition of Candida krusei ABC1 expressed in Saccharomyces cerevisiae isolate ADdelta at 7 nM2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Abc1p is a multidrug efflux transporter that tips the balance in favor of innate azole resistance in Candida krusei.
AID1759465Antifungal activity against Candida tropicalis incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID542410Inhibition of Candida albicans inositol phosphorylceramide synthase2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID1759441Antifungal activity against Cryptococcus neoformans PFCC 93-589 assessed as TOS production at 2 times MIC incubated for 10 mins measured per mg of protein by colorimetric method (Rvb = 1.63 umol)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759438Antifungal activity against Cryptococcus neoformans PFCC 93-589 assessed as inhibition of melanin production at 0.5 times MIC incubated for 2 to 10 days2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759464Antifungal activity against Candida glabrata incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759427Antifungal activity against Cryptococcus neoformans PFCC 93-589 by broth microdilution assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID542415Irreversible inhibition of Candida albicans ATCC 38247 inositol phosphorylceramide synthase2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID1759462Antifungal activity against Aspergillus flavus incubated for 48 hrs by broth microdilution method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759445Hemolytic activity in human RBC at 1 ug/ml incubated for 30 mins2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759463Antifungal activity against Candida albicans incubated for 24 hrs by broth microdilution method2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759435Antifungal activity against Cryptococcus neoformans PFCC 93-589 after 7 days in absence of sorbitol by microdilution assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759440Antifungal activity against Cryptococcus neoformans PFCC 93-589 assessed as TOS production at 1 times MIC incubated for 10 mins measured per mg of protein by colorimetric method (Rvb = 1.19 umol)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759469Antifungal activity against Cryptococcus neoformans PFCC 93-589 in presence of fluconazole by checkerboard microtiter assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1233919Time dependent inhibition of Candida albicans ATCC 38247 membrane inositol phosphorylceramide synthase using ceramide as substrate2015ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6
Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A.
AID542404Inhibition of Candida albicans ATCC 38247 inositol phosphorylceramide synthase2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID542405Inhibition of Candida albicans ATCC 38247 inositol phosphorylceramide synthase preincubated for 30 mins2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID542407Inhibition of aureobasidin A-resistant Saccharomyces cerevisiae inositol phosphorylceramide synthase preincubated for 30 mins2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID1759456Upregulation of Lac1 gene expression in Cryptococcus neoformans PFCC 93-589 assessed as fold increase in protein level at 2 ug/ml by SYBR green based RT-PCR analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759446Hemolytic activity in human RBC at 0.5 ug/ml incubated for 30 mins2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759449Cytotoxicity against human HEK293 cells assessed as cell survival at 0.5 times MIC incubated for 24 hrs by MTT assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759425Fungicidal activity against Cryptococcus neoformans PFCC 93-589 by broth microdilution assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1233882Antifungal activity against Candida albicans by broth dilution method2015ACS medicinal chemistry letters, Jun-11, Volume: 6, Issue:6
Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A.
AID542411Inhibition of Saccharomyces cerevisiae inositol phosphorylceramide synthase2009Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2
Inhibition of inositol phosphorylceramide synthase by the cyclic peptide aureobasidin A.
AID1759448Cytotoxicity against human HEK293 cells assessed as cell survival at 0.25 times MIC incubated for 24 hrs by MTT assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759429Inhibition of ergosterol biosynthesis in Cryptococcus neoformans PFCC 93-589 cell membrane assessed as ergosterol content at 0.5 times MIC incubated for 48 hrs by UV-visible spectrophotometric analysis (Rvb = 0.134 No_unit)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759439Antifungal activity against Cryptococcus neoformans PFCC 93-589 assessed as TOS production at 0.5 times MIC incubated for 10 mins measured per mg of protein by colorimetric method (Rvb = 1.04 umol)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759434Antifungal activity against Cryptococcus neoformans PFCC 93-589 after 2 days in presence of sorbitol by microdilution assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759452Induction of morphological changes in Cryptococcus neoformans PFCC 93-589 assessed as excessive vacuolization at 2 ug/ml after 48 hrs by TEM analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759430Inhibition of ergosterol biosynthesis in Cryptococcus neoformans PFCC 93-589 cell membrane at 0.5 times MIC incubated for 48 hrs by UV-visible spectrophotometric analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759432Inhibition of ergosterol biosynthesis in Cryptococcus neoformans PFCC 93-589 cell membrane at 1 times MIC incubated for 48 hrs by UV-visible spectrophotometric analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759457Downregulation of Cxt1p gene expression in Cryptococcus neoformans PFCC 93-589 assessed as fold decrease in protein level at 2 ug/ml by SYBR green based RT-PCR analysis2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759443Hemolytic activity in human RBC at 4 ug/ml incubated for 30 mins2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759471Downregulation of Cxt1p gene expression in Cryptococcus neoformans PFCC 93-589 at 2 ug/ml by SYBR green based RT-PCR analysis relative to control2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
AID1759444Hemolytic activity in human RBC at 2 ug/ml incubated for 30 mins2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Inhibitory effects and mechanism of antifungal action of the natural cyclic depsipeptide, aureobasidin A against Cryptococcus neoformans.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (33.33)18.2507
2000's4 (44.44)29.6817
2010's1 (11.11)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.23 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-butanol
1-Butanol: A four carbon linear hydrocarbon that has a hydroxy group at position 1.. butan-1-ol : A primary alcohol that is butane in which a hydrogen of one of the methyl groups is substituted by a hydroxy group. It it produced in small amounts in humans by the gut microbes.		2.0210alkyl alcohol;
primary alcohol;
short-chain primary fatty alcohol		human metabolite;
mouse metabolite;
protic solvent
choline
[no description available]		2.0210cholinesallergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter;
nutrient;
plant metabolite;
Saccharomyces cerevisiae metabolite
fluconazole
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.		2.5220conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug		environmental contaminant;
P450 inhibitor;
xenobiotic
flucytosine
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.		2.0510aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone		prodrug
itraconazole
[no description available]		2.0510piperazines
ketoconazole
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.		2.0510dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine
miconazole
Miconazole: An imidazole antifungal agent that is used topically and by intravenous infusion.. 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]imidazole : A member of the class of imidazoles that is 1-(2,4-dichlorophenyl)-2-(imidazol-1-yl)ethanol in which the hydroxyl hydrogen is replaced by a 2,4-dichlorobenzyl group.. miconazole : A racemate composed of equimolar amounts of (R)- and (S)-miconazole. Used (as its nitrate salt) to treat skin infections such as athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.		2.0510dichlorobenzene;
ether;
imidazoles
trifluoperazine
[no description available]		2.0510N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines		antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug
4-nitroquinoline-1-oxide
4-nitroquinoline N-oxide : A quinoline N-oxide carrying a nitro substituent at position 4.		2.0510C-nitro compound;
quinoline N-oxide		carcinogenic agent
1,2-dipalmitoylphosphatidylcholine
1,2-Dipalmitoylphosphatidylcholine: Synthetic phospholipid used in liposomes and lipid bilayers to study biological membranes. It is also a major constituent of PULMONARY SURFACTANTS.		2.0210
cycloheximide
Cycloheximide: Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis.. cycloheximide : A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus.		2.0510antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol		anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor
nigericin
Nigericin: A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus. (From Merck Index, 11th ed). nigericin : A polyether antibiotic which affects ion transport and ATPase activity in mitochondria. It is produced by Streptomyces hygroscopicus.		2.0510polycyclic etherantibacterial agent;
antimicrobial agent;
bacterial metabolite;
potassium ionophore
voriconazole
Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.		2.0510conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug		P450 inhibitor
monensin
Monensin: An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies.. monensin A : A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle.		2.0510cyclic hemiketal;
monocarboxylic acid;
polyether antibiotic;
spiroketal		antifungal agent;
coccidiostat;
ionophore
ergosterol
[no description available]		2.05103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
ergostanoid;
phytosterols		fungal metabolite;
Saccharomyces cerevisiae metabolite
latrunculin a
latrunculin A: 16-membered macrolide attached to 2-thiazolidinone moiety; from Red Sea sponge Latrunculia magnifica; see also latrunculin B; structure given in first source. latrunculin A : A bicyclic macrolide natural product consisting of a 16-membered bicyclic lactone attached to the rare 2-thiazolidinone moiety. It is obtained from the Red Sea sponge Latrunculia magnifica and from the Fiji Islands sponge Cacospongia mycofijiensis. Latrunculin A inhibits actin polymerisation, microfilament organsation and microfilament-mediated processes.		2.0510cyclic hemiketal;
macrolide;
oxabicycloalkane;
thiazolidinone		actin polymerisation inhibitor;
metabolite;
toxin
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		2.0510macrolide lactambacterial metabolite;
immunosuppressive agent
terbinafine
[no description available]		2.0510acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine		EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.830antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
cerulenin
Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.		2.0510epoxide;
monocarboxylic acid amide		antifungal agent;
antiinfective agent;
antilipemic drug;
antimetabolite;
antimicrobial agent;
fatty acid synthesis inhibitor
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		210homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
cytochalasin d
[no description available]		2.0510
khafrefungin
khafrefungin: inhibits inositol phosphoceramide synthase in fungi; structure in first source		2.0510
rhodamine 123
[no description available]		2.0510organic chloride salt;
xanthene dye		fluorochrome
nystatin a1
Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.		2.0510nystatins
ConditionIndicatedRelationship StrengthStudiesTrials
Candida Infection
[description not available]		02.0510
Candidiasis
Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed)		02.0510
C gattii Infection
[description not available]		0210
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		0210
Cerebral Cryptococcosis
[description not available]		0210
Cryptococcosis
Fungal infection caused by genus CRYPTOCOCCUS.		0210
Meningitis, Cryptococcal
Meningeal inflammation produced by CRYPTOCOCCUS NEOFORMANS, an encapsulated yeast that tends to infect individuals with ACQUIRED IMMUNODEFICIENCY SYNDROME and other immunocompromised states. The organism enters the body through the respiratory tract, but symptomatic infections are usually limited to the lungs and nervous system. The organism may also produce parenchymal brain lesions (torulomas). Clinically, the course is subacute and may feature HEADACHE; NAUSEA; PHOTOPHOBIA; focal neurologic deficits; SEIZURES; cranial neuropathies; and HYDROCEPHALUS. (From Adams et al., Principles of Neurology, 6th ed, pp721-2)		0210
chemdatabank.com